Category Archives: Cell Biology

CZI announces grants for researchers studying the role of inflammation in disease – News-Medical.Net

Reviewed by Emily Henderson, B.Sc.Apr 29 2020

Today, the Chan Zuckerberg Initiative (CZI) announced $14 million in funding to support 29 interdisciplinary teams and build a network of researchers that will explore emerging ideas regarding the role of inflammation in disease. While inflammation is a natural defense that helps our bodies maintain a healthy state, chronic inflammation results in harmful diseases such as asthma, arthritis, and heart disease.

In this cohort, we welcome 80 researchers working on the projects, 75 percent of which are led by early-career scientists within six years of starting their independent position. Grantee teams are made up of two to three investigators with distinct areas of expertise, including physicians, experimental biologists, technology developers, and computational scientists. The awarded project teams represent 11 countries. View the full list of grantees.

Knowing more about inflammation at the level of affected cells and tissues will increase our understanding of many diseases and improve our ability to cure, prevent, or manage them. We look forward to collaborating with these interdisciplinary teams of researchers studying inflammation."

Cori Bargmann, CZI Head of Science

CZI will support these small teams to carry out two-year pilot projects focused on tissue-level inflammatory processes in diverse tissues and disease states. Several researchers are studying coronaviruses like SARS and MERS. Pilot awards are intended to help new collaborations form, establish technologies and experimental methods, and frame key questions for further investigation.

"Work on inflammation has been distributed among many fields and lacks dedicated support as a coherent discipline," said CZI Science Program Officer, Jonah Cool. "As these research teams study the cells involved in inflammation -- and the molecular mechanisms that link them -- we hope to support community growth and connect advances in inflammation that will have far-reaching impact."

Inflammation plays a role in organ failure, neurodegenerative diseases like Alzheimer's, and severe infectious diseases like COVID-19. Diseases associated with inflammation disproportionately affect underserved communities and vulnerable populations, highlighting the importance of making progress in this area of biology. Several funded projects will directly explore important differences depending on genetic ancestry and lifestyle.

These grants build on CZI's work in single-cell biology supporting the Human Cell Atlas, a fundamental reference for health and disease. Inflammation grantees are encouraged to think broadly about how collaboration and new technologies can be used to bring clarity to a question that touches so many diseases.

View original post here:
CZI announces grants for researchers studying the role of inflammation in disease - News-Medical.Net

UVa researchers hope better understanding of spinal cord cells will aid treatment – The Daily Progress

University of Virginia scientists are exploring why nerve cells die after spinal cord injuries research that they hope could improve treatments.

Jonathan Kipnis, and Kodi Ravichandran, professors at the UVa School of Medicine, have received $350,00 from the Chan Zuckerberg Initiative in support of their research, the university announced.

Using a probe developed by Ravichandran, the two researchers are planning to track nerve cells after they die and are swallowed up by immune cells, or phagocytes, that remove them from the body. They want to see what type of cells are involved in the bodys response to a spinal cord injury and how they work.

Knowing what cell type is the phagocyte at the site of damage would allow us to specifically target that cell type or subtype of cells to eat more of the cellular debris after the brain or spinal cord injury, said Ravichandran, chairman of the Department of Microbiology, Immunology and Cancer Biology, in a news release.

The pairs funding is part of a $14 million effort from the institute for 29 interdisciplinary teams to explore the role of inflammation in various diseases.

Kipnis said in a news release Ravichandrans expertise in phagocytes complements his work as director of UVas Brain Immunology and Glia Center.

Merging complementary expertise and focusing on one common goal could lead to a real scientific breakthrough, said Kipnis, chairman of the Department of Neuroscience and director of UVAs Brain Immunology and Glia Center.

Follow this link:
UVa researchers hope better understanding of spinal cord cells will aid treatment - The Daily Progress

Global Cell And Tissue Analysis Products Market with Coronavirus (Covid-19) Effect Analysis | likewise Industry is Booming Globaly with Key Players…

Cell And Tissue Analysis Products Market Global and outlook (2015 2025)

The report published onCell And Tissue Analysis Productsis a invaluable foundation of insightful data helpful for the decision-makers to form the business strategies related R&D investment, sales and growth, key trends, technological advancement, emerging market and more. The global Cell And Tissue Analysis Products market report includes key facts and figures data which helps its users to understand current scenario of the global market along with anticipated growth. The Cell And Tissue Analysis Products market report contains quantitative data such as global sales and revenue (USD Million) market size of different categories and sub categories such as regions, CAGR, market shares, revenue insights of market players, and others. The report also gives qualitative insights on the global Cell And Tissue Analysis Products market, that gives the exact outlook of the global as well as country level Cell And Tissue Analysis Products market.

Click Here To Access The Free Sample Report:http://www.marketresearchstore.com/report/global-cell-and-tissue-analysis-products-market-report-289478#RequestSample

Major Companies Profiled in the Global Cell And Tissue Analysis Products Market are: Danaher, Luminex, EMD Millipore Corporation, PARTEC, GE Healthcare, Thermo Fisher Scientific, BD, Mindray, PerkinElmer, Miltenyi Biotec

The focus of the global Cell And Tissue Analysis Products market report is to define, categorized, identify the Cell And Tissue Analysis Products market in terms of its parameter and specifications/ segments for example by product, by types, by applications, and by end-users. This study also provides highlights on market trends, market dynamics (drivers, restrains, opportunities, challenges), which are impacting the growth of Cell And Tissue Analysis Products market.

By Type the Cell And Tissue Analysis Products market is segmented into: Cell & Tissue Characterization Products, Bio specimens, Cell Separation Products

By Application the Cell And Tissue Analysis Products market is segmented into: Drug Discovery and Development, Stem Cell Research, Cell Biology, Other Research Practices

For Any Query Regarding the Cell And Tissue Analysis Products Market Report? Contact Us at:http://www.marketresearchstore.com/report/global-cell-and-tissue-analysis-products-market-report-289478#InquiryForBuying

Regions covered in this study are North America, Europe, Middle East & Africa, Latin America, and Asia Pacific. These regions are further analyzed based on the major countries in it. Countries analyzed in the scope of the report are the U.S., Canada, Germany, the UK, France, Spain, Italy, China, India, Japan, South Korea, Southeast Asia countries, Australia, Brazil, Mexico, GCC countries, South Africa, and Turkey among others.

Significant aspects of the Reports and Main Highlights:

A detailed look at the Cell And Tissue Analysis Products Industry Changing business trends in the global Cell And Tissue Analysis Products market Detailed market bifurcation analysis at different level such as type, application, end user, Regions / countries Historical and forecast size of the Cell And Tissue Analysis Products market in terms of Revenue (USD Million) Recent industry development and market trends Competitive Landscape and player positioning analysis for the Cell And Tissue Analysis Products market Key Product Offerings by Major players and business strategies adopted Niche and Potential segments (ex. types, applications, and regions/countries) anticipated to observed promising growth Key challenges faced by operating players in the market space Analysis of major risks associated with the market operations

Browse Full Research Report Now@http://www.marketresearchstore.com/report/global-cell-and-tissue-analysis-products-market-report-289478

Read more here:
Global Cell And Tissue Analysis Products Market with Coronavirus (Covid-19) Effect Analysis | likewise Industry is Booming Globaly with Key Players...

Increasing Demand for Cytokines Market to Substantially Surge the Revenues Through the COVID-19 Lockdown Phase and Forecast 2019 2029 Cole Reports -…

Cytokines are the cell signaling molecules which are secreted from the different body cells. Cytokines are the proteins which play an important role of messenger between cells and regulates various physiological and metabolic activities. Cytokines regulate various inflammatory responses, stimulate blood cells production, and stimulate tissue development & maintenance. Cytokine is a large family of the small protein which includes tumors necrosis factor, interleukins, interferons, lymphokines and chemokines. Cytokines are produced by a wide range of cells includes cells like macrophages, lymphocytes, T lymphocytes, endothelial cells, mast cells, fibroblasts, stromal cells and cells. Some cytokines developed into protein therapeutics to treat bone-related disorders, anemia, cancer, infection, multiple sclerosis. Cytokine is most commonly used in the research & development activities in the field of life sciences and drug development.

Request to Sample report @ https://www.persistencemarketresearch.com/samples/30223

Increasing research and development activities expected to favour the growth of the cytokines market. As well as growing life science research funding boost up the growth of the cytokines market. Increasing prevalence of diseases such as cancer and skin disorders expected to drive the growth of the cytokines market. The growing demand for regenerative medicines impels the growth of the cytokines market. The growing demand for cytokines for wound management and cancer therapeutics expected to drive the growth of the market. Growing funding for cancer-based research influencing the growth of cytokines market. Growing cell culture-based research activities and increasing demand for cytokines in stem cell biology are major factors expected to drive the growth of the cytokines market. Growing manufacturers investments in cell culture media production expected to favour the growth of the growth factors market over the forecast period. Growing strategic acquisition and merger activities among market players is the major trend in the cytokines market. The high cost of research-based cytokines products is the major factor expected to restrain the growth of the cytokines market.

Request PMR insights on measuring the impact of COVID-19 coronavirus across industries.

The global cytokines market is segmented on basis of product type, application, end users and region:

Cytokine is the large family of cytokines includes tumour necrosis factor-TNF, interleukins (IL), interferons, chemokines and other cytokines. Interleukins (IL) is the most commonly used cytokine and have large family. IL-1 family, IL-4 family, IL-6 family, IL-10 family are mostly commonly used interleukins family in the research. Cytokines are used in various field of the research such as dermatology, cancer, orthopedics, respiratory and other fields. Cytokines are used for the research application among end users such as pharmaceutical & biotechnology companies, contract research organizations and academic & research institutes.

North America expected to dominate the global cytokines market as increasing demand for cytokines products as increasing research and development activities. Europe expected to contribute second-highest revenue share in global cytokines market as a growing number of clinical trial and drug development activities. The Asia Pacific expected to grow with the highest growth rate in the cytokines market as an increasing number of pharmaceutical manufacturers, biotechnology companies and academic institutions in the Asia Pacific region. India, South Korea & China cytokines market expected to grow with a higher growth rate as growing research and development funding from the government. The Middle East & Africa cytokines market expected to grow with the lowest growth rate due to lack of research and development activities in the region.

Request to View TOC @ https://www.persistencemarketresearch.com/toc/30223

Some of the players operating in the global cytokines market are ,

For in-depth competitive analysis, buy [emailprotected] https://www.persistencemarketresearch.com/checkout/30223

View original post here:
Increasing Demand for Cytokines Market to Substantially Surge the Revenues Through the COVID-19 Lockdown Phase and Forecast 2019 2029 Cole Reports -...

ETH Zurich researchers study higher rates of COVID-19 deaths in the elderly – Science Business

As we age, our lung tissue becomes stiffer and this is a phenomenon that SARS-CoV-2 may be exploiting. Caroline Uhler and G. V. Shivashankar outline their hypothesis.

The new coronavirus strikes both young and old. But the more severe cases and the higher rates of death are amongthe elderly. The reason for this is as yet unknown. Some scientists suspect that this may be related to the weakening of the immune system in the elderly indeed, senior citizens are known to be more susceptible to many infectious diseases.

However, there may be other explanations. As we grow older, the structure, mechanical properties and functions of the cells in our body change. Its conceivable that SARS-CoV-2 takes advantage of these conditions and reproduces better in cells of older people, which in turn would lead to a more severe disease progression.1 In our opinion, its worthwhile examining this hypothesis more closely. For if we can ascertain exactly how the virus behaves in the cells of older people, we will know which cell functions to target with drugs. This information could be critical in the search for drugs against COVID-19.

Stiffening of the lung tissue with age

When the new coronavirus infects humans, it first attacks the mucosal cells of the respiratory tract. Once the virus gets inside a cell, it hijacks its cellular processes to produce masses of new viruses, which the cell eventually releases ready to infect the next cell in the body or other people via droplets from sneezing or coughing. While the new coronavirus has been observed to invade cells in both young and old people, the outcome is often different. Why should this be so?

Its known that the lung and respiratory tract tissue stiffens with age. This is partly due to the connective tissue cells in these organs, which deposit more protein fibres in the tissue with age. The stiffening in turn has an influence on the mechanical properties and processes inside the mucosal cells, and even on the genetic control of their cell functions. In recent years, we have demonstrated this connection between mechanics and cell function.2

Since coronaviruses depend on the functions of their host cells in order to multiply, and these functions in turn depend on the mechanical properties of the cell, we suspect that the mechanics and functions of cells in older people may favour the multiplication of the virus. Biopsies or cell culture experiments could now be used to determine whether this is indeed the case.

Keeping an eye on behaviour

Our reasoning can also indicate where to concentrate additional efforts in the quest for drugs to combat COVID-19. One focus of research is to stall the viral entry into a cell. Scientists are currently looking to develop inhibitors to prevent the virus from infecting cells in this way. Given our hypothesis, and that coronavirus entry into a cell is similar even in those with mild symptoms, the quest for drugs should also include inhibitors that intersect with coronavirus replication and the mechanical properties of cells.

We plan to develop in-vitro models and machine learning methodology that will be well-suited for testing the effectiveness of small molecules, both approved drugs that could be repurposed and newly developed ones. Its essential that research on SARS-CoV-2 focus not just on the virus itself, but also on how the virus behaves in the cells of young and old people. And we should look not only at the genomic differences between these cells, but also at their mechanical differences.

References

1 Uhler C, Shivashankar GV: Mechano-genomic regulation of coronaviruses and its interplay with ageing. Nature Reviews Molecular Cell Biology 2020, doi: 10.1038/s41580-020-0242-z

2 Uhler C, Shivashankar GV: Regulation of genome organization and gene expression by nuclear mechanotransduction. Nature Reviews Molecular Cell Biology 2017. 18: 717, doi: 10.1038/nrm.2017.101

This article was first published on 28 April by ETH Zurich.

Read the original:
ETH Zurich researchers study higher rates of COVID-19 deaths in the elderly - Science Business

Rapid Advancements in Single Use Technologies Biologic Market to Fuel Revenues Through 2021 Cole Reports – Cole of Duty

Single-use, also known as disposable, refers to products that are intended for one-time use. These products are made from a plastic (polyamide {PA}, polyethylene {PE}, polycarbonate {PC}, polyethersulfone {PESU}, polypropylene {PP}, polyvinyl chloride {PVC}, polytetrafluorethylene {PTFE}, cellulose acetate {CA}, and ethylene vinyl acetate {EVA}) and are disposed after use.

Single-use products have revolutionized the field of bioproduction. These products are becoming popular in the biopharmaceutical arena as they reduce the risk of contamination during development and production. Various disposable products such as laboratory instruments, including petri plates, flasks, filling and tubing systems, cell culture apparatus, filters, pumps, bioreactors, are used in bioproduction.

Single-use technologiesare mainly used in bio-therapeutic development and manufacturing processes. These technologies facilitate the development of small amounts of drug products for use in preclinical and clinical testing procedures.

The global single-use technologies market is categorized based on technology and application. Based on technology, the report covers membrane adsorber, bioreactors, disposable mixing systems, tangential flow filtration, tubing and connectors, depth filtration, buffer containers, waste containers and media bags, and filter cartridges. The application segment is further sub-segmented into monoclonal antibodies, vaccines, gene therapy, recombinant proteins, and blood derivatives.

Get Sample Copy of Report @https://www.persistencemarketresearch.com/samples/4220

In terms of geography, North America dominates the global single-use technologies market. This is due to improved biopharmaceutical industry in the region. Moreover, increased awareness about therapeutic applications of biotherapeutics has also fueled the market in North America. The U.S. represents the largest market for single-use technologies in North America, followed by Canada. In Europe, Germany, France, and the U.K. hold major shares of the single-use technologies market.

The single-use technologies market in Asia too, is expected to experience high growth rate over the next five years. This is due to improving Life Sciences arena in the region. Furthermore, increased foreign investment in this field is also supporting the growth of the single-use technologies market in the region. India, China, and Japan are expected to be the fastest growing markets for single-use technologies in Asia.

Rising awareness about therapeutic applications of biotherapeutics is a key driver for the global single-use technologies market. Also, increasing demand of biologics and advancements in medical technology are fuelling the growth of this market. Low manufacturing and maintenance costs of single-use products and instruments attract end-users to adopt this technology in bioproduction. Increasing research on cell biology and stem cell is propelling the demand for single-use products.

Request Customization of this Report @https://www.persistencemarketresearch.com/request-customization/4220

Moreover, drug pricing control is forcing large and emerging biotech companies to change their overall approach in development and production of bioproducts. This is leading to rise in demand for improved process optimization and more efficient operations such as single-use technologies and bioengineering. This is creating growth opportunities for single use-use technologies market.

However, stringent regulations imposed by various governments hamper the growth of global single-use technologies market. Increasing number of mergers and acquisitions of biotech and pharmaceutical companies and rapid product launches are key trends in the global single-use technologies market.

For In-depth Competitive Analysis, Pre-Book Report Now @ https://www.persistencemarketresearch.com/checkout/4220

Market Players

The major companies operating in this market are :

See the original post:
Rapid Advancements in Single Use Technologies Biologic Market to Fuel Revenues Through 2021 Cole Reports - Cole of Duty

resTORbio and Adicet Bio Merge to Advance T-Cell Therapies – BioSpace

Boston-based resTORbio and Menlo Park, California-based Adicet Bio announced plans to combine into a single company. The merged company will focus on developing Adicets off-the-shelf allogeneic gamma delta T-cell therapies for cancer and other indications.

Under the terms of the deal, Adicet shareholders will receive shares of newly issued resTORbio common stock. Adicet shareholders are expected to own about 75% of the combined company, with current resTORbio equityholders owning the remaining 25%.

The deal is expected to close in the second half of 2020. Once finalized, the combined company will run under the name Adicet Bio and is expected to trade on the Nasdaq Global Market under a new ticker symbol, which hasnt been announced yet. It will maintain offices in Menlo Park and Boston.

After the merger, Chen Schor will act as president and chief executive officer; Stewart Abbot as senior vice president, chief operating officer and scientific officer; Francesco Galimi will be senior vice president and chief medical officer; Lloyd Klickstein will act as chief innovation officer; Carrie Krehlik will be senior vice president and chief human resource officer; and Joan Mannick will serve as head of Infectious Diseases.

Anil Singhal, formerly Adicets president and chief executive officer, will act as an advisor to the board of directors.

On behalf of the Adicet Board, we thank Anil for his service to Adicet and welcome his contributions as an advisor to the board of directors, said Carl Gordon, member of Adicets board.

The deal is an all-stock transaction.

After a thorough evaluation of strategic alternatives, the board of directors of resTORbio believes that this merger represents the highest-potential value creation opportunity for resTORbio stockholders, said Schor. The combined company will leverage Adicets scientific and product development expertise and pipeline of engineered immune cell therapeutics for cancer based on its proprietary gamma delta T-cell therapy platform. We believe this transformative transaction will provide the resources for the combined company to advance multiple programs into the clinic, including Adicets lead candidate, ADI-001, a gamma delta CAR-T cell therapy targeting CD20, and expand the pipeline in oncology and other indications.

They also indicate that after the merge, they expect to continue developing RTB101, resTORBios small molecule product candidate for COVID-19. The drug is a potent inhibitor of the rapamycin complex 1 (TORC1), with clinical data expected in the first quarter of 2021.

The deal terms also consider a contingent value right (CVR) that will be distributed to resTORbio stockholders immediately before the merger, which gives CVR holders the possibility of net proceeds from the commercialization, if any, of RTB101.

Adicet was founded in 2015 by Aya Jakobovits to develop off-the-shelf immune cell therapies. It is also working to identify and validate cancer-specific targets from the intracellular proteome and generating TCRL s (T-cell receptor-like) to the cancer-specific peptide targets presented by MHC Class I complexes.

resTORbio focuses on the biology of aging to treat aging-related diseases. Its lead program selectively inhibits TORC1, an evolutionarily conserved pathway that is associated with aging.

See more here:
resTORbio and Adicet Bio Merge to Advance T-Cell Therapies - BioSpace

Interview with the new IRD CEO on the coronavirus – Explica

Sciences et Avenir: One of your first decisions was to create a scientific committee to consolidate the decisions to be taken to deal with the epidemic in the countries of the south. What do you expect?

Valrie Verdier: We are facing a new situation caused by a virus of which we really know little. We therefore have to resolve medical questions, assess the health situation in each country where we are asked, model the evolution of the pandemic, think about the deployment of measures to combat the coronavirus. This requires mobilizing skills in epidemiology, virology, ecology, anthropology, sociology, scientific fields on which the IRD relies in its daily action. Faced with the coronavirus, we must reinforce this interdisciplinarity and the first mission of the committee will be precisely to work together on a global approach. It is made up of four IRD scientists and four partners from the South in order to reflect in particular on strategies for implementing diagnostics with African researchers. This is a fundamental principle of the Institute: the IRD laboratories are co-constructed and co-managed with our partners.

What are the requests made by your African counterparts?

This concerns the means of screening, understanding the spread of the virus, the implementation of control measures: containment, barrier gestures, etc. Thus the UMR TransVIHMI of Montpellier animates the Coronavirus Africa project (Coraf) intended to respond quickly to the social questions raised by the epidemic and to enlighten the decision-makers by comparing in particular the initiatives in Senegal, Burkina-Faso and Benin. Another project, Corafmob, analyzes social distancing and community mobilizations in Senegal and Burkina-Faso. The IRD also supports patient monitoring and the implementation of diagnostic methods deployed in Cameroon, Guinea and the Democratic Republic of Congo (DRC). The French Development Agency (AFD) has just granted us 2.2 million euros for the implementation of an action research project which supports the African response to the epidemic in Benin, Ghana , in Guinea, Senegal, Cameroon and the DRC, the Ariacov project. With our partners the National Institute of Biomedical Research in the DRC, the National Institute of Public Health in Guinea or the West African Center for Cell Biology of Infectious Pathogens in Ghana, to name but three we will put set up a set of activities combining training, equipment and consumables to carry out large-scale screening tests and carry out the sero-epidemic surveys necessary to develop modeling. We will also strengthen quantitative data collection systems, coupled with qualitative surveys and monitoring of the media and social networks, to better understand the knowledge that populations have of epidemic risk, so that decision-makers can adapt the messages of prevention if necessary. However, we are still facing a glaring lack of tests. We cannot imagine today testing the only people at risk, nor even the nursing staff.

What do we know about the dynamics of the epidemic in Africa?

Few things unfortunately. There currently seem to be relatively few cases listed. One of my Malian colleagues told me at the end of April that his country was at the very beginning of the epidemic. We must quickly build models for forecasting the evolution of the epidemic adapted to the African continent. Those used in Europe are not necessarily suitable. First, the age pyramid is completely different: in France, almost 30% of the population is over 60, while in Guinea for example, people over 65 represent only 3% of the population. However, it is the elderly who are most at risk from coronavirus, while the young seem to cope better, or are asymptomatic. Furthermore, living conditions can make the spread of the disease different. In Europe, a sick person can infect 3 to 10 other people, in Africa it is potentially much more.

Do the shortcomings of African health systems not cause the worst fear?

We dont start from scratch. There are health infrastructures and our African colleagues have a very good knowledge of the methods to be implemented against epidemics. The fight against Ebola and HIV has made it possible to build strategies to limit the spread of disease and health structures know how to react as best as possible to an epidemic. There is strong experience that local authorities can rely on to limit the spread of Covid-19. What we all want to avoid is that people with the disease have to go to big cities to get tested and treated. It is imperative to relocate the offer of test and care, otherwise the populations risk not being able to be taken care of.

Sciences et Avenir: One of your first decisions was to create a scientific committee to consolidate the decisions to be taken to deal with the epidemic in the countries of the south. What do you expect?

Valrie Verdier: We are facing a new situation caused by a virus of which we really know little. We therefore have to resolve medical questions, assess the health situation in each country where we are contacted, model the evolution of the pandemic, think about the deployment of measures to combat the coronavirus. This requires mobilizing skills in epidemiology, virology, ecology, anthropology, sociology, scientific fields on which the IRD relies in its daily action. Faced with the coronavirus, we must reinforce this interdisciplinarity and the first mission of the committee will be precisely to work together on a global approach. It is made up of four IRD scientists and four partners from the South in order to reflect in particular on strategies for implementing diagnostics with African researchers. This is a fundamental principle of the Institute: the IRD laboratories are co-constructed and co-managed with our partners.

What are the requests made by your African counterparts?

This concerns the means of screening, understanding the spread of the virus, the implementation of control measures: containment, barrier gestures, etc. The Montpellier TransVIHMI research unit leads the Coronavirus Africa project (Coraf), which is intended to respond quickly to the social questions raised by the epidemic and enlighten decision-makers by notably comparing initiatives in Senegal, Burkina-Faso and Benin. Another project, Corafmob, analyzes social distancing and community mobilizations in Senegal and Burkina-Faso. The IRD also supports patient monitoring and the implementation of diagnostic methods deployed in Cameroon, Guinea and the Democratic Republic of Congo (DRC). The French Development Agency (AFD) has just granted us 2.2 million euros for the implementation of an action research project which supports the African response to the epidemic in Benin, Ghana , in Guinea, Senegal, Cameroon and the DRC, the Ariacov project. With our partners the National Institute of Biomedical Research in the DRC, the National Institute of Public Health in Guinea or the West African Center for Cell Biology of Infectious Pathogens in Ghana, to name but three we will put set up a set of activities combining training, equipment and consumables to carry out large-scale screening tests and carry out the sero-epidemic surveys necessary to develop modeling.

Read more:
Interview with the new IRD CEO on the coronavirus - Explica

Exosomes: Definition, Function and Use in Therapy – Technology Networks

What are exosomes?

Exosomes are a class of cell-derived extracellular vesicles of endosomal origin, and are typically 30-150 nm in diameter the smallest type of extracellular vesicle.1 Enveloped by a lipid bilayer, exosomes are released into the extracellular environment containing a complex cargo of contents derived from the original cell, including proteins, lipids, mRNA, miRNA and DNA.2 Exosomes are defined by how they are formed through the fusion and exocytosis of multivesicular bodies into the extracellular space.

Multivesicular bodies* are unique organelles in the endocytic pathway that function as intermediates between early and late endosomes.3 The main function of multivesicular bodies is to separate components that will be recycled elsewhere from those that will be degraded by lysosomes.4 The vesicles that accumulate within multivesicular bodies are categorized as intraluminal vesicles while inside the cytoplasm and exosomes when released from the cell.

*Confusingly, there is inconsistency in the literature; while some sources differentiate multivesicular bodies from late endosomes, others use the two interchangeably.

Exosomes are of general interest for their role in cell biology, and for their potential therapeutic and diagnostic applications. It was originally thought that exosomes were simply cellular waste products, however their function is now known to extend beyond waste removal. Exosomes represent a novel mode of cell communication and contribute to a spectrum of biological processes in health and disease.2One of the main mechanisms by which exosomes are thought to exert their effects is via the transfer of exosome-associated RNA to recipient cells, where they influence protein machinery. There is growing evidence to support this, such as the identification of intact and functional exosomal RNA in recipient cells and certain RNA-binding proteins have been identified as likely players in the transfer of RNA to target cells.5,6 MicroRNAs and long noncoding RNAs are shuttled by exosomes and alter gene expression while proteins (e.g. heat shock proteins, cytoskeletal proteins, adhesion molecules, membrane transporter and fusion proteins) can directly affect target cells.7,8Exosomes have been described as messengers of both health and disease. While they are essential for normal physiological conditions, they also act to potentiate cellular stress and damage under disease states.2

Multivesicular bodies are a specialized subset of endosomes that contain membrane-bound intraluminal vesicles. Intraluminal vesicles are essentially the precursors of exosomes, and form by budding into the lumen of the multivesicular body. Most intraluminal vesicles fuse with lysosomes for subsequent degradation, while others are released into the extracellular space.9,10 The intraluminal vesicles that are secreted into the extracellular space become exosomes. This release occurs when the multivesicular body fuses with the plasma membrane.

The formation and degradation of exosomes.

This is an active area of research and it is not yet known how exosome release is regulated. However, recent advances in imaging protocols may allow exosome release events to be visualized at high spatiotemporal resolution.11

Exosomes have been implicated in a diverse range of conditions including neurodegenerative diseases, cancer, liver disease and heart failure. Like other microvesicles, the function of exosomes likely depends on the cargo they carry, which is dependent on the cell type in which they were produced.12 Researchers have studied exosomes in disease through a range of approaches, including:

In cancer, exosomes have multiple roles in metastatic spread, drug resistance and angiogenesis. Specifically, exosomes can alter the extracellular matrix to create space for migrating tumor cells.13,14 Several studies also indicate that exosomes can increase the migration, invasion and secretion of cancer cells by influencing genes involved with tumor suppression and extracellular matrix degradation.15,16Through general cell crosstalk, exosomal miRNA and lncRNA affect the progression of lung diseases including chronic obstructive pulmonary disease (COPD), asthma, tuberculosis and interstitial lung diseases. Stressors such as oxidant exposure can influence the secretion and cargo of exosomes, which in turn affect inflammatory reactions.17 Altered exosomal profiles in diseased states also imply a role for exosomes in many other conditions such as in neurodegenerative diseases and mental disorders.18,19Cells exposed to bacteria release exosomes which act like decoys to toxins, suggesting a protective effect during infection.20 In neuronal circuit development, and in many other systems, exosomal signaling is likely to be a sum of overlapping and sometimes opposing signaling networks.21

Exosomes can function as potential biomarkers, as their contents are molecular signatures of their originating cells. Due to the lipid bilayer, exosomal contents are relatively stable and protected against external proteases and other enzymes, making them attractive diagnostic tools. There are increasing reports that profiles of exosomal miRNA and lncRNA differ in patients with certain pathologies, compared with those of healthy people.17 Consequently, exosome-based diagnostic tests are being pursued for the early detection of cancer, diabetes and other diseases.22,23Many exosomal proteins, nucleic acids and lipids are being explored as potential clinically relevant biomarkers.24 Phosphorylation proteins are promising biomarkers that can be separated from exosomal samples even after five years in the freezer25, while exosomal microRNA also appears to be highly stable.26 Exosomes are also highly accessible as they are present in a wide array of biofluids (including blood, urine, saliva, tears, ascites, semen, colostrum, breast milk, amniotic fluid and cerebrospinal fluid), creating many opportunities for liquid biopsies.

Exosomes are being pursued for use in an array of potential therapeutic applications. While externally modified vesicles suffer from toxicity and rapid clearance, membranes of naturally occurring vesicles are better tolerated, offering low immunogenicity and a high resilience in extracellular fluid.27 These naturally-equipped nanovesicles could be therapeutically targeted or engineered as drug delivery systems.

Exosomes bear surface molecules that allow them to be targeted to recipient cells, where they deliver their payload. This could be used to target them to diseased tissues or organs.27 Exosomes may cross the blood-brain barrier, at least under certain conditions28 and could be used to deliver an array of therapies including small molecules, RNA therapies, proteins, viral gene therapy and CRISPR gene-editing.

Different approaches to creating drug-loaded exosomes include27:

Exosomes hold huge potential as a way to complement chimeric antigen receptor T (CAR-T) cells in attacking cancer cells. CAR exosomes, which are released from CAR-T cells, carry CAR on their surface and express a high level of cytotoxic molecules and inhibit tumor growth.29 Cancer cell-derived exosomes carrying associated antigens have also been shown to recruit an antitumor immune response.30

The purification of exosomes is a key challenge in the development of translational tools. Exosomes must be differentiated from other distinct populations of extracellular vesicles, such as microvesicles (which shed from the plasma membrane, also referred to as ectosomes or shedding vesicles) and apoptotic bodies.31 Although ultracentrifugation is regarded as the gold standard for exosome isolation, it has many disadvantages and alternative methods for exosome isolation are currently being sought. Exosome isolation is an active area of research (see Table 1) and many research groups are seeking ways to overcome the disadvantages listed below, while navigating the relevant regulatory hurdles along the way.

Produces a low yield and low purity of the isolated exosomes as other types of extracellular vesicles have similar sedimentation properties.

Low efficiency as it is labor-intensive, time-consuming and requires a large amount of sample. specialized equipment. High centrifugal force can damage exosome integrity

See the article here:
Exosomes: Definition, Function and Use in Therapy - Technology Networks

A day in the COVID-19 life of a working mom and USC biology lab manager – USC News

Morning dawns on Gorjana Bezmalinovic with a nuzzle and smooch from Rey, her German shepherd. Since mid-March, life for USCs lab manager of undergraduate biology classes has been a case study in extreme multitasking. Since she began working at home, shes had to help homeschool her two children, support her husband during hard times and shift all 800 of her students to online learning.

Bezmalinovics daughter, Lara, shows off the molted lobster exoskeleton she found while exploring. (Photo/Courtesy of Gorjana Bezmalinovic)

I had peace and quiet when I was at work, but I dont now, Bezmalinovic said. Working at home means working more than ever.

Out of bed and into the kitchen, she makes coffee and scans emails because students love to send emails in the middle of the night. Her daughter Lara, 8, gets up first, followed by her son, Niko, 15. Then its time to make breakfast. Next, the 47-year-old mom helps Lara get started on her homework before returning to her USC responsibilities.

On a good day, its not easy managing two introductory biology classes, one honors class, 20 teaching assistants, seven professors and 800 students. But life for Bezmalinovic, who coordinates the needs of this sprawling enterprise, changed dramatically when classes moved online last month.

Many of the students are pre-med, pre-veterinary or pre-dental. They study evolution, ecology, cell biology and physiology. The courses are not easy-peasy. Kids who come from small towns are shocked at the size of the classes, she said.

Her biggest challenge was figuring out how to teach dissection online. Students were disappointed that they might miss disassembling a frog or lamb heart or testing blood types rites of passage in undergraduate biology. Bezmalinovic scrambled for solutions.

Working with her assistants, she cobbled together online instructional videos that helped students complete the exercises from the lab manual, YouTube dissection videos and an online blood transfusion video game. Her lab instructors recorded their Zoom lectures, and voil, she had a virtual lab.

Lunchtime at home means preparing a meal for the kids, then sending them outside to walk the dog so I gain 30 minutes of peace and quiet, she said. The rest of the afternoon, she works with her teaching assistants. The living room is her office. Her family uses the other rooms for school and business.

Bezmalinovic came to USC in 2006 as a lecturer after completing her graduate degree at California State University, Long Beach. Prior, she lived in Croatia and attended college there. She loved science and jumped at the opportunity to manage USCs biology courses.

Most of all, she enjoys working with the students. She remembers their names; they call her Mrs. B. Shes their advisor, lecturer, administrator and counselor, available at all times of the day.

Then comes dinner time and Mrs. B is mom again, feeding a hungry family. She helps her kids with their studies then spends time with her husband.

The family dog, Rey, accompanies Bezmalinovic during a break from work. (Photo/Courtesy of Gorjana Bezmalinovic)

He says, I thought now that youre working from home wed have more time, but its crazier than usual. He wants to talk at 8 or 9 p.m., but I cant because theres always something to do. If I leave a task for tomorrow, Ill have much more to do the next day, Bezmalinovic said.

At the end of the semester, shes working on a lab exam and student presentations. Then come the final exams and grading, followed by planning for online summer classes. In a normal year, her family would vacation with relatives in Croatia, but COVID-19 wiped out that summer trip.

If theres consolation, its the fact she doesnt have to commute to work or worry about picking up her daughter from school.

Im more relieved that I dont have to be stuck in traffic, but theres too little time in the day to do everything, she said. But you know, I love helping the students. They like me, and Im always in a good mood with them. I love my job. I wouldnt have it any other way.

At days end, she walks Rey around the neighborhood, unplugged with no phone. Its 40 minutes of quiet comfort with the dog that will be there in the morning to get her started all over again.

Karla Reid contributed to this story.

More stories about: Biology, COVID-19, Staff

Read more here:
A day in the COVID-19 life of a working mom and USC biology lab manager - USC News